Torrey Pines Investment

Torrey Pines Investment, founded in 2002, is a specialty life-science investment company located in San Diego. Torrey Pines has a team of investment professionals with extensive experience in entrepreneurship, venture capital and operations. Our firm has created biopharma incubators investing in early development stage assets from international pharma and biotech partners in CNS, oncology, and virology areas to bring them to commercial success through pharma partnering and M&A. We are committed to capitalizing on the unique opportunities in biotech and pharma, where we can add value in development or regulatory strategy by utilizing resources of our portfolio CRO companies. We seek to leverage our industry knowledge, network of industry and financial contacts, and internal resources to assist our portfolio management in developing and executing their business strategy. Our bottom line is to help our companies achieve growth, build value and realize wealth.

Christopher J. Cummings

Investment Professional

Gelena Lifchitz

Business Development Director

Nikolay Savchuk

Managing Director

21 past transactions

Viriom

Convertible Note in 2017
Viriom Inc. is a biotechnology company focused on developing innovative and affordable treatments for life-threatening infections, particularly HIV/AIDS and hepatitis B virus (HBV). Founded in 2009 and based in Khimki, Russia, Viriom holds exclusive worldwide licenses for its lead compounds, Elpida (elsulfavirine) and VM1500A, which are in phase 3 and commercial stages of development. The company has also created proprietary drug candidates, including VM2500 and VM3500 LAI formulations, along with combinations that integrate cell, vaccine, and antibody therapies. Viriom aims to make significant advancements in the treatment, prevention, and potential cure of HIV and chronic HBV infections globally.

TealTech MMO

Venture Round in 2017
TealTech MMO develop a way to avoid unnecessary travel, waiting and worry when you do not feel well. What if instead of coming to a doctor, a doctor will come to you? There are already doctors doing home calls, but still most of the primary care is provided in clinics, since medical equipment and laboratory are not portable. Digital era changes the game. With point-of-care diagnostics, secure cloud data-bases and telemedicine we can make doctor’s office portable. Miniaturization of diagnostic and laboratory devices along with telecommunication helps to avoid travel, waiting and exposure to other patient’s pathogens by replacing the unnecessary ER/Urgent care visits with a professional care in the comfort of patient’s home. Mobile Office Point-of-Care lab ensures hospital quality rapid blood, and urine testing 24/7 along with instrumental tests and on-line consultations’ by specialists. We enable family doctors to continuously serve their patients - after hours, during weekends and travel time. The key elements are: · Care in the comfort of patients’ home (nurse house call visits within 1.5 hour after a call) · Point-of-care diagnostics enabling results of lab and instrumental tests in minutes during the house call visit; · Providing a patient with tools to objectively monitor health parameters and communicate them to the doctor at any time; · Dramatic reduction of the paperwork for doctors and nurses allowing to spend more time with a patient; · Control the quality of care by peer reviews (second opinion) and patient evaluation of the services and results of the treatment; Service Traveling nurses visit patients at home, provide on-site diagnostics and communication with primary physicians and specialists to treat a wide spectrum of diseases. Nurses come equipped with hospital grade POC diagnostic instruments to provide quality care 24/7 and replace costly ER visits for non-life threatening conditions. Product The product consists of hardware and software. The hardware is a set of FDA-approved portable diagnostic devices including blood cell counter, blood chemistry, coagulation meter, urine analyzer, pathogen and biomarker detecting devices, ultrasound, ECG, vital signs monitor, digital stethoscope and multipurpose video camera. All devices are connected to the laptop and packed in the convenient lightweight case that fits in the trunk of the car and can be easily delivered to the patient’s bed. The software enables automatic secure transfer of the test and lab results from devices into the patient records and further to any EHR. The friendly interface tailored to primary care needs reduces the amount of time physicians spend on paperwork and patient evaluation by automating diagnosis, prescription creation, and progress notes. Unlike other EMRs the system works in on-line and off-line mode and could be applied at any patient site independent of Internet accessibility. Mobile Medical Office platform connects patients with healthcare providers, enabling scheduling of house call visits similar to scheduling Uber taxi rides as well as secured video chat with a doctor or a team of doctors.

Chromis Therapeutics

Seed Round in 2016
Chromis Therapeutics, Inc. (Chromis) is a San Diego-based biopharmaceutical company, focused on the development of curative treatments for chronic HBV infection, based on its advanced proprietary drug design and discovery platform. The company is seeking investment to advance its novel cccDNA inhibitor (CHR101), viral entry and viral capsid assembly inhibitor lead candidates for the treatment of chronic HBV. CHR101 has a potential to eradicate HBV and to efficiently cure chronically infected HBV patients, as compared to drugs currently on the market. CHR101's activity is supported by a robust discovery preclinical data package.

Viriom

Convertible Note in 2016
Viriom Inc. is a biotechnology company focused on developing innovative and affordable treatments for life-threatening infections, particularly HIV/AIDS and hepatitis B virus (HBV). Founded in 2009 and based in Khimki, Russia, Viriom holds exclusive worldwide licenses for its lead compounds, Elpida (elsulfavirine) and VM1500A, which are in phase 3 and commercial stages of development. The company has also created proprietary drug candidates, including VM2500 and VM3500 LAI formulations, along with combinations that integrate cell, vaccine, and antibody therapies. Viriom aims to make significant advancements in the treatment, prevention, and potential cure of HIV and chronic HBV infections globally.

Chromis Therapeutics

Seed Round in 2016
Chromis Therapeutics, Inc. (Chromis) is a San Diego-based biopharmaceutical company, focused on the development of curative treatments for chronic HBV infection, based on its advanced proprietary drug design and discovery platform. The company is seeking investment to advance its novel cccDNA inhibitor (CHR101), viral entry and viral capsid assembly inhibitor lead candidates for the treatment of chronic HBV. CHR101 has a potential to eradicate HBV and to efficiently cure chronically infected HBV patients, as compared to drugs currently on the market. CHR101's activity is supported by a robust discovery preclinical data package.

Viriom

Convertible Note in 2015
Viriom Inc. is a biotechnology company focused on developing innovative and affordable treatments for life-threatening infections, particularly HIV/AIDS and hepatitis B virus (HBV). Founded in 2009 and based in Khimki, Russia, Viriom holds exclusive worldwide licenses for its lead compounds, Elpida (elsulfavirine) and VM1500A, which are in phase 3 and commercial stages of development. The company has also created proprietary drug candidates, including VM2500 and VM3500 LAI formulations, along with combinations that integrate cell, vaccine, and antibody therapies. Viriom aims to make significant advancements in the treatment, prevention, and potential cure of HIV and chronic HBV infections globally.

Leap Therapeutics

Seed Round in 2015
Leap Therapeutics, Inc., a clinical-stage biopharmaceutical company, is engaged in acquiring and developing novel therapeutics. The company focus is to identify translational-stage molecules in the areas of cell signaling and immuno-oncology.

Avelas Biosciences

Series B in 2014
Avelas BioSciences, Inc. is a clinical stage biotechnology company that focuses on developing technologies that advance care for cancer surgery and therapeutic intervention. It develops AVB-620, an intravenously administered in vivo fluorescent protease-activatable peptide that detects, marks, and diagnoses cancer. The company was incorporated in 2008 and is based in La Jolla, California.

T23 Biopharmaceutical

Venture Round in 2014
T23 is pre-clinical and clinical stage biopharmaceutical Company. Located at Torrey Pines Investment campus in San Diego, CA it is focused on development of novel targeted immunotherapies for treatment of patients with cancer and autoimmune disease. T101, their candidate conjugate of siglec ligand and nanosomal formulation is currently in pre-clinical development with other conjugates in discovery.

Precision Repair Network

Venture Round in 2014
We are here to help with all of your wheelchair safety and repair needs! At the Precision Repair Network, we can improve your mobility, independence, and quality of life. We accomplish this through power wheelchair repair and service. A national association of highly- trained service engineers and technicians, we provide service throughout the contiguous 48 states to meet our members' needs – and we always come to you. If you rely on a power wheelchair or scooter for mobility, don't settle for less. At the Precision Repair Network, we can empower you to take charge of your life.

Avelas Biosciences

Series B in 2014
Avelas BioSciences, Inc. is a clinical stage biotechnology company that focuses on developing technologies that advance care for cancer surgery and therapeutic intervention. It develops AVB-620, an intravenously administered in vivo fluorescent protease-activatable peptide that detects, marks, and diagnoses cancer. The company was incorporated in 2008 and is based in La Jolla, California.

TeaRx

Seed Round in 2012
TeaRx Ltd. engages in the development of drugs for the prevention of thrombosis-related illnesses. The company is based in Moscow, Russian Federation.

SatRx

Seed Round in 2012
SatRx LLC is a biotechnology company that focuses on drug discovery, development, and commercialization of treatments for diabetes, obesity, cardiovascular, and other metabolic diseases; and transplantology therapies in the CIS region. The company was founded in 2010 and is based in Khimki, Russian Federation. SatRx LLC operates as a subsidiary of ChemRar Ltd.

Biointegrator

Seed Round in 2012
BioIntegrator, Ltd. is a biotechnology company based in the Russian Federation that specializes in the development and manufacturing of pharmaceutical products utilizing recombinant proteins and other macromolecules. As a subsidiary of ChemRar Ltd., BioIntegrator focuses on creating innovative therapeutic solutions to address various medical needs. The company leverages advanced biotechnological processes to enhance the efficacy and safety of its pharmaceutical offerings. With a commitment to research and development, BioIntegrator aims to contribute to the advancement of healthcare through its specialized products.

Tensha Therapeutics

Funding Round in 2012
Tensha Therapeutics is developing small molecule bromodomain inhibitors, a new class of epigenetic modulators of gene expression, to treat cancer and other serious disorders. The company‟s programs are based on the discovery from the laboratory of Dr. James Bradner at Dana-Farber Cancer Institute of first-in-class, potent small molecule BET bromodomain inhibitors. The company‟s lead program is aimed at the treatment of patients with BRD4-NUT midline carcinoma, acute myeloid leukemias, multiple myeloma, and other diseases. Tensha is a Focused Company funded by HealthCare Ventures.

Avionco

Seed Round in 2012
Organization

NewVac

Seed Round in 2012
NewVac

Aviron

Seed Round in 2012
Aviron Ltd engages in the research and development of specific antiviral agents against chronic Hepatitis C Virus (HCV) infection. The company has strategic alliances with CHEMRAR Hi-Tech Center, Chemical Diversity Research Institute, and DRUGS TECHNOLOGY, Ltd. Aviron Ltd was founded in 2010 and is based in Moscow, Russian Federation.

Avineuro

Seed Round in 2011
Avineuro Pharmaceuticals, Inc. discovers and develops molecules/compounds for the treatment of neurological and psychiatric disorders. Its products include AVN-211, a drug for psychiatric/anxiety disorders; and AVN-322, a drug for Alzheimer disease. The company has strategic partnerships with ChemDiv, Inc.; and Drugs Technology. Avineuro Pharmaceuticals, Inc. was founded in 2008 and is based in San Diego, California.

Viriom

Seed Round in 2009
Viriom Inc. is a biotechnology company focused on developing innovative and affordable treatments for life-threatening infections, particularly HIV/AIDS and hepatitis B virus (HBV). Founded in 2009 and based in Khimki, Russia, Viriom holds exclusive worldwide licenses for its lead compounds, Elpida (elsulfavirine) and VM1500A, which are in phase 3 and commercial stages of development. The company has also created proprietary drug candidates, including VM2500 and VM3500 LAI formulations, along with combinations that integrate cell, vaccine, and antibody therapies. Viriom aims to make significant advancements in the treatment, prevention, and potential cure of HIV and chronic HBV infections globally.

Allachem

Seed Round in 2008
AllaChem, LLC is engaged in the invention, discovery, and development of drugs, including drugs for treating infectious diseases, cancer, and CNS disorders. Its products in development include AV4025, a Phase 1a clinical study completed product for the treatment of chronic hepatitis C infection; AVR560, which is in clinical development for HCV; AV5075C and AV5080, the oral drug candidates that are in pre-clinical development stage for the treatment of flu; and ONC1-13B, an anti-androgen, which is a pre-clinical studies completed compound for the treatment of prostate and breast cancers. The company was founded in 2004 and is based in Hallandale Beach, Florida.